Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 26, 2022 01:00 ET | Source: Novartis Pharma AG

Novartis erzielt ein solides Umsatz- und Gewinnwachstum. Die starke Performance auf dem Markt befindlicher Marken stützt das Vertrauen in die mittelfristigen Wachstumsaussichten

Ad-hoc-Mitteilung gemäss Art. 53 KR Der Umsatz stieg im ersten Quartal um +5% (kWk1, +1% USD), das operative Kernergebnis wuchs um +9% (kWk, +3% USD) Innovative Medicines (IM) steigerte den Umsatz...
April 26, 2022 01:00 ET | Source: Novartis Pharma AG

Novartis: solide croissance du chiffre d’affaires et du bénéfice. La forte performance des marques existantes soutient la confiance dans les prévisions de croissance à moyen terme

Annonce événementielle selon l’art. 53 RC Chiffre d’affaires du T1 en hausse de +5% (tcc1, +1% USD) et résultat opérationnel core en progression de 9% (tcc, +3% USD) Innovative Medicines (IM):...
April 26, 2022 01:00 ET | Source: Novartis Pharma AG

Novartis delivers solid sales and profit growth. Strong performance of in-market brands supports confidence in mid-term growth outlook

Ad hoc announcement pursuant to Art. 53 LR Q1 sales grew +5% (cc1, +1% USD), core operating income grew +9% (cc, +3% USD) Innovative Medicines (IM) sales grew +4% (cc, +1% USD) and core...
April 22, 2022 09:27 ET | Source: Novartis Pharma AG

Novartis receives positive CHMP opinion for Tabrecta® for patients with METex14 advanced non-small cell lung cancer

Opinion based on Phase II GEOMETRY mono-1 study showing an overall response rate (ORR) of 51.6% in a cohort evaluating second-line patients only and 44% in all previously-treated patients with...
April 14, 2022 01:15 ET | Source: Novartis Pharma AG

Sandoz launches generic brimonidine tartrate/timolol maleate eyedrop in US for patients with ocular hypertension, expanding leading ophthalmic portfolio

Brimonidine tartrate/timolol maleate combination eyedrop is used to treat elevated eye pressure in patients with ocular hypertension1 Ocular hypertension affects over 5% of all adults2; the eye does...
April 06, 2022 01:15 ET | Source: Novartis Pharma AG

Sandoz extends collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)

Extending existing master services agreement with Ares Genetics, to develop digital platform for development and life cycle management of antibiotics, to January 31, 2025Both parties strengthening...
April 05, 2022 20:29 ET | Source: Novartis Pharma AG

FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)

Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a spectrum of rare conditions and is characterized by...
April 05, 2022 01:15 ET | Source: Novartis Pharma AG

Novartis expands Zolgensma manufacturing capacity with approval of multi-product North Carolina facility

Clearance of critical milestone expands capability for production of gene therapies, starting with Zolgensma® Basel, April 5, 2022 – Novartis today announced the U.S. Food and Drug Administration...
April 04, 2022 01:00 ET | Source: Novartis Pharma AG

Novartis gibt neue Organisationsstruktur bekannt für schnelleres Wachstum, eine stärkere Pipeline und höhere Produktivität

Ad-hoc-Mitteilung gemäss Art. 53 KRDie neue, vereinfachte Struktur und Organisation werden die Strategie von Novartis als fokussiertes Arzneimittelunternehmen unterstützen und die nächste Phase...
April 04, 2022 01:00 ET | Source: Novartis Pharma AG

Novartis announces new organizational structure to accelerate growth, strengthen pipeline and increase productivity

Ad hoc announcement pursuant to Art. 53 LRNew simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of...